Lurbinectedin in combination with pembrolizumab in relapsed SCLC

A phase 1/2 trial of lurbinectedin (L) in combination with ...

A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.

P48.06 Lurbinectedin in Combination with Pembrolizumab for ...

P48.06 Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed Small Cell Lung Cancer. LUPER Clinical Trial · Introduction. Small cell lung ...

1989MO Lurbinectedin (LUR) in combination with pembrolizumab ...

1989MO Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study · Background · Methods.

LUPER Study Results: Lurbinectedin + Pembrolizumab in Relapsed ...

The authors concluded that the combination of lurbinectedin + pembrolizumab is effective and accompanied by a manageable safety profile in second-line treatment ...

Preliminary Results Show Second-line Lurbinectedin Plus ...

Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab ...

Lurbinectedin in combination with pembrolizumab in relapsed SCLC

Andrea Ardizzoni, MD, PhD, University of Bologna, Bologna, Italy, shares findings from the LUPER study (NCT04358237) which aimed to explore ...

PharmaMar presents new data on lurbinectedin for Small Cell Lung ...

Zepzelca® (lurbinectedin), Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): the phase 1/2 ...

Lurbinectedin in combination with pembrolizumab in relapsed SCLC

Andrea Ardizzoni, MD, PhD, University of Bologna, Bologna, Italy, shares findings from the LUPER study (NCT04358237) which aimed to explore ...

P48.06 Lurbinectedin in Combination with Pembrolizumab for ...

Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed Small Cell Lung Cancer. LUPER Clinical Trial. M.J. De Miguel Luken,1 B.G. Doger ...

lurbinectedin in combination with pembrolizumab in relapsed SCLC

Antonio Calles Blanco, MD, Gregorio Maranon General University Hospital, Madrid, Spain, discusses results from the LUPER study (NCT04358237) ...

A phase 1/2 trial of lurbinectedin (L) in combination with ...

A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study. Antonio Calles ...

SCLC - Annals of Oncology

Lurbinectedin (LUR) in combination with pembrolizumab. (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II. LUPER study. A. Calles Blanco1, A.F. ...

Lurbinectedin (PM01183) Combined With Pembrolizumab in Small ...

In the multicenter, open-label LUPER trial, patients with relapsed SCLC will receive lurbinectedin plus pembrolizumab (Keytruda). During the phase 1 portion, ...

Antonio Calles, MD, Highlights Promising Preliminary Activity of ...

Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected ...

Lurbinectedin in small cell lung cancer - PMC - PubMed Central

The recommended flat dose of lurbinectedin was 4 mg in the combined regimen. Twenty-seven patients with relapsed SCLC were treated with the above therapy.

lurbinectedin in combination with pembrolizumab in relapsed SCLC

Antonio Calles Blanco, MD, Gregorio Maranon General University Hospital, Madrid, Spain, discusses results from the LUPER study (NCT04358237) ...

Investigators Set Sights on Novel Agents Following Negative ...

... lurbinectedin in combination with pembrolizumab (Keytruda) in the relapsed setting. ... relapsed small cell lung cancer (SCLC): The LUPER study.

A phase 1/2 trial of lurbinectedin (L) in combination with ...

A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study. June 2022; Journal ...

Considerations for selecting second-line treatment in patients with ...

This review highlights key considerations regarding selection of second-line treatment for patients with relapsed SCLC. In particular, the role of lurbinectedin ...

Efficacy and toxicity of lurbinectedin in subsequent systemic therapy ...

Relapsed small cell lung cancer (SCLC) is classified according to the chemotherapy-free interval of either 6 months or 3 months, as per the ...